Speaker Profile

Ph.D., Co-director, Genetic Pharmacology Service; Associate Professor, Cincinnati Children’s Hospital Medical Center

Biography
Dr. Ramsey’s lab is interested in all aspects of pharmacogenetics, from basic research to implementation in patient care. Pharmacogenetics refers to the effect of a person's genetic code on their response to a medication. She study many different types of medications for many diseases. She found that pharmacogenetic variants influenced the response, toxicity and dosing of antidepressants in children, then implemented clinical decision support with dosing guidelines through Cincinnati Children’s Genetic Pharmacology Service to optimize dosing and potentially avoid side effects. Dr. Ramsey led an international group of experts in creating a consensus guideline for when to use glucarpidase. She also developed a web tool (mtxpk.org) that shows clinicians how an individual patient is predicted to eliminate methotrexate and whether they meet the indication criteria for glucarpidase. She is a recipient of the Darrell Abernethy Early Stage Investigator Award from the American Society for Clinical Pharmacology & Therapeutics (2019).

Talk
Implementing Pharmacogenetics in Pediatrics
Dr. Ramsey will discuss how the influence of pharmacogenetics changes during development, which medications with pharmacogenetic-based dosing guidelines are prescribed most often in pediatrics, and how Cincinnati Children’s Hospital Medical Center implemented pharmacogenetics in routine care.


 Session Abstract – PMWC 2022 Silicon Valley


Track Chairs:
Philip Empey, UPitt
Mary V. Relling, St. Jude Children’s Research Hospital
Stuart Scott, Stanford

Pharmacists have long recognized that using unique patient characteristics to guide pharmacotherapy decision-making can improve drug response and mitigate drug-associated risks. Age, weight, and dietary habits were among the first patient-specific characteristics used to individualize pharmacotherapy. As technologies advanced, analytic tools that measure surrogate markers of liver and renal function, together with drug concentrations in biological fluids, were adopted to optimize therapeutic regimens. Cutting-edge genomic technologies are now being integrated into patient care for the selection of targeted therapies and identification of those at increased risk of poor pharmacotherapy outcomes. We’re excited to bring together experts who are advancing pharmacogenomics at scale through cutting edge clinical implementation, research, and education.

  • Keynote: The Future Of PGx
    - Julie Johnson, University of Florida
  • PGx Research and Discovery
    - Estenab Burchard, UCSF
    - William Evans, St. Jude's
    - Jose Estabil, Cipherome
    - James Coons, UPMC
    - Todd Skaar, Indiana University
  • Innovative Industry Solutions
    - Jeffrey A. Shaman, Coriell Life Sciences
    - Akwasi Asabere, Helix
    - Gillian Bell, Genome Medical
    - Cindy Kosinski, 23andme
  • Key Resources for PGx
    - Kelly E. Caudle, St. Jude Children’s Research Hospital
    - Michelle Whirl-Carillo, Stanford
  • Clinical Laboratory PGx Considerations
    - Ulrich Broeckel, MCW
    - Stuart Scott, Stanford
    - Victoria Pratt, Indiana University
  • Lessons from Frontline PGx Clinical Services
    - Mark H. Dunnenberger, Northshore University HealthSystem
    - Lucas Berenbrok, UPitt
    - Sony Tuteja, UPenn
    - Burns Blaxall, The Christ Hospital Health Network
  • Translational PGx Implementation Programs
    - Philip Empey, UPitt
    - Julie A. Johnson, Uinversity of Florida
    - Mary V. Relling, St. Jude Children’s Research Hospital
    - Laura Ramsey, Cincinnati Children's Hospital
    - Nita A. Limdi, UAB